DVAX

Dynavax Technologies Corporation [DVAX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

DVAX Stock Summary

Top 10 Correlated ETFs

DVAX


Top 10 Correlated Stocks

DVAX


In the News

07:39 29 Mar 2024 DVAX

Dynavax Technologies: Still A Believer

Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.

07:34 29 Mar 2024 DVAX

Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript

Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript

06:16 29 Mar 2024 DVAX

Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4

Dynavax Technologies (DVAX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.45 per share a year ago.

10:34 29 Mar 2024 DVAX

Dynavax Technologies (DVAX) Is a Great Choice for 'Trend' Investors, Here's Why

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

06:33 29 Mar 2024 DVAX

Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif. , Jan. 3, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 42nd Annual J.P.

01:53 29 Mar 2024 DVAX

Dynavax Technologies: Still A Solid Pick For 2024

Today, we take another look at Dynavax Technologies Corporation, which experienced a boost in revenue from the Covid pandemic, but this has now nearly completely diminished. However, the company's core asset is the HEPLISAV-B, a vaccine for Hepatitis B, which has gained market share and achieved high compliance rates. Third quarter results showed strong performance for HEPLISAV-B, leading to an increase in sales guidance for 2023. Analysts also expect a rebound in earnings and sales in 2024.

10:31 29 Mar 2024 DVAX

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

09:46 29 Mar 2024 DVAX

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

05:04 29 Mar 2024 DVAX

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

EMERYVILLE, Calif. , Nov. 20, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m.

11:17 29 Mar 2024 DVAX

Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year?

Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

DVAX Financial details

Company Rating
Buy
Market Cap
1.61B
Income
-6.39M
Revenue
232.28M
Book val./share
4832.27
Cash/share
5766.21
Dividend
-
Dividend %
-
Employees
408
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
29.35
Forward P/E
28.86
PEG
0.28
P/S
4.98
P/B
2.97
P/C
0
P/FCF
20.51
Quick Ratio
14.14
Current Ratio
15.4
Debt / Equity
0.41
LT Debt / Equity
0.41
-
-
EPS (TTM)
33.07
EPS next Y
0.43
EPS next Q
-0.02
EPS this Y
-101.7%
EPS next Y
-98.71%
EPS next 5Y
-96.07%
EPS last 5Y
-52.72%
Revenue last 5Y
45.83%
Revenue Q/Q
-20.02%
EPS Q/Q
30009.09%
-
-
-
-
SMA20
-3.93%
SMA50
-12.96%
SMA100
-13.94%
Inst Own
78.6%
Inst Trans
0.79%
ROA
6%
ROE
11%
ROC
0.05%
Gross Margin
67%
Oper. Margin
13%
Profit Margin
17%
Payout
-
Shs Outstand
130.62M
Shs Float
130.22M
-
-
-
-
Target Price
-
52W Range
9.48-15.15
52W High
-17.27%
52W Low
+37.89%
RSI
47.88
Rel Volume
0.24
Avg Volume
2.01M
Volume
475.94K
Perf Week
3.24%
Perf Month
-0.56%
Perf Quarter
-14%
Perf Half Y
-12.85%
-
-
-
-
Beta
1.255
-
-
Volatility
0.13%, 0.35%
Prev Close
0%
Price
12.41
Change
-0.56%

DVAX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.490.463.37.121.8
Net income per share
-2.1-0.910.582.89-0.05
Operating cash flow per share
-1.68-0.922.520.620.78
Free cash flow per share
-2.09-1.032.450.550.75
Cash per share
2.11.644.16.155.77
Book value per share
0.120.581.675.724.83
Tangible book value per share
0.050.561.665.74.82
Share holders equity per share
0.120.581.675.724.83
Interest debt per share
3.282.352.022.612.05
Market cap
411.98M448.35M1.87B1.08B1.8B
Enterprise value
588.54M634.12M1.69B1.14B1.91B
P/E ratio
-2.72-4.8924.393.68-281.69
Price to sales ratio
11.79.634.261.497.75
POCF ratio
-3.4-4.865.5817.2217.9
PFCF ratio
-2.73-4.345.7419.4318.66
P/B Ratio
49.77.648.421.862.89
PTB ratio
49.77.648.421.862.89
EV to sales
16.7113.623.851.578.21
Enterprise value over EBITDA
-5.13-9.4411.93.8190.87
EV to operating cash flow
-4.85-6.875.0418.1118.96
EV to free cash flow
-3.91-6.145.1920.4419.76
Earnings yield
-0.37-0.20.040.270
Free cash flow yield
-0.37-0.230.170.050.05
Debt to equity
26.483.711.160.440.41
Debt to assets
0.790.620.250.260.26
Net debt to EBITDA
-1.54-2.77-1.260.195.08
Current ratio
3.632.951.094.5613.81
Interest coverage
-7.16-3.9512.0342.12-5.48
Income quality
0.791.234.370.21-15.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
01.70.230.180.66
Research and developement to revenue
1.770.610.070.060.24
Intangibles to total assets
0.020.01000
Capex to operating cash flow
0.240.12-0.03-0.11-0.04
Capex to revenue
-0.83-0.24-0.02-0.01-0.02
Capex to depreciation
-1.37-1.19-1.35-1.07-0.56
Stock based compensation to revenue
0.720.290.050.050.18
Graham number
2.333.464.6619.292.32
ROIC
-0.45-0.290.260.32-0.06
Return on tangible assets
-0.55-0.260.070.3-0.01
Graham Net
-1.28-0.8-1.063.553.32
Working capital
139.34M151.31M50.88M533.77M796.93M
Tangible asset value
3.71M56.4M220.25M579.01M620.01M
Net current asset value
-78.39M-65.85M-209.59M279M484.1M
Invested capital
26.483.711.160.440.41
Average receivables
6.3M15.77M77.24M139.67M96.02M
Average payables
7.28M6.3M2.96M2.91M4.23M
Average inventory
30.18M52.51M62.51M60.39M56.37M
Days sales outstanding
92.09177.68109.4974.569.98
Days payables outstanding
174.6686.915.474.4738.16
Days of inventory on hand
778.081.67K128.9882.77387.72
Receivables turnover
3.962.053.334.95.22
Payables turnover
2.094.266.7681.649.56
Inventory turnover
0.470.222.834.410.94
ROE
-18.26-1.560.340.5-0.01
Capex per share
-0.41-0.11-0.07-0.07-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.220.370.40.45431.87
Net income per share
0.45-0.190.020.091.7
Operating cash flow per share
0.230.220.180.2106.93
Free cash flow per share
0.220.210.180.293.55
Cash per share
4.125.14.484.675.77K
Book value per share
3.834.413.793.924.83K
Tangible book value per share
3.824.393.783.914.82K
Share holders equity per share
3.834.413.793.924.83K
Interest debt per share
1.712.031.71.682.02K
Market cap
1.61B1.25B1.97B2.28B1.8M
Enterprise value
1.67B1.33B2B2.38B108.43M
P/E ratio
5.96-12.89143.2339.842.05
Price to sales ratio
8.7526.7432.6332.760.03
POCF ratio
46.1945.4370.0973.160.13
PFCF ratio
48.3947.6472.0273.990.15
P/B Ratio
2.782.233.413.760
PTB ratio
2.782.233.413.760
EV to sales
9.0528.4433.1434.181.95
Enterprise value over EBITDA
23.98-137.34269.49160.1419.77
EV to operating cash flow
47.848.3171.1976.337.88
EV to free cash flow
50.0750.6773.1577.199
Earnings yield
0.04-0.0200.010.12
Free cash flow yield
0.020.020.010.016.69
Debt to equity
0.440.460.450.430.41
Debt to assets
0.260.270.280.260.26
Net debt to EBITDA
0.8-8.24.186.6419.44
Current ratio
4.569.0717.7815.413.81
Interest coverage
37.49-10.64-2.423.03-3.36
Income quality
0.52-1.148.172.1862.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.170.780.620.550.74
Research and developement to revenue
0.070.290.220.20.25
Intangibles to total assets
00000
Capex to operating cash flow
-0.05-0.05-0.03-0.01-0.13
Capex to revenue
-0.01-0.03-0.010-0.03
Capex to depreciation
-1.1-0.78-0.42-0.19-0.88
Stock based compensation to revenue
0.050.210.180.150.2
Graham number
6.24.341.392.86430.07
ROIC
0.07-0.0200.010
Return on tangible assets
0.07-0.0300.010
Graham Net
2.372.742.522.673.32K
Working capital
533.77M738.63M752.6M781.4M796.93M
Tangible asset value
579.01M561.69M575.17M602.94M620.01M
Net current asset value
279M423.95M438.23M467.65M484.1M
Invested capital
0.440.460.450.430.41
Average receivables
139.32M124.63M73.55M46.11M45.7M
Average payables
3.13M5.25M5.27M3.18M4.18M
Average inventory
81.03M58.57M55.39M51.25M51.35M
Days sales outstanding
71.96195.1367.7560.6872.09
Days payables outstanding
3.7344.6321.5821.2354.33
Days of inventory on hand
69.04352.93352.95336.16551.97
Receivables turnover
1.250.461.331.481.25
Payables turnover
24.132.024.174.241.66
Inventory turnover
1.30.260.250.270.16
ROE
0.12-0.040.010.020
Capex per share
-0.01-0.0100-13.38

DVAX Frequently Asked Questions

What is Dynavax Technologies Corporation stock symbol ?

Dynavax Technologies Corporation is a US stock , located in Emeryville of Ca and trading under the symbol DVAX

What is Dynavax Technologies Corporation stock quote today ?

Dynavax Technologies Corporation stock price is $12.41 today.

Is Dynavax Technologies Corporation stock public?

Yes, Dynavax Technologies Corporation is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap